Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study - Concepedia

Concepedia

Publication | Closed Access

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

98

Citations

24

References

2010

Year

Denis Talbot, Malcolm Ranson, J.N.P. Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher A. Slapak, Anna L Olsen,

Clinical Cancer Research

Abstract

The tumor-specific, molecularly targeted effects demonstrated by this ASO in man underpin confirmatory studies evaluating its therapeutic efficacy in cancer.

References

	Year	Citations

Page 1